Take a trial of Europe to unlock this pageFind out more

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2009 2010 2011 2012 2013 2014 2015E 2016E CAGR / Avg
Revenue $m
Operating Profit $m
Net Profit $m
EPS Reported $
EPS Normalised $
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps $
Capex ps $
Free Cashflow ps $
Dividend ps $
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc $m
Working Capital $m
Net Fixed Assets $m
Net Debt $m
Book Value $m
Average Shares m
Book Value ps $ -20.9%

FINANCIAL BRIEF: For the fiscal year ended 31 December 2014, MDxHealth SA revenues increased 55% to $11.7M. Net loss decreased 6% to $15.3M. Revenues reflect Government Grant Income increase from $0K to $192K. Lower net loss reflects Labor & Related Expenses in SGA decrease of 40% to $1.5M (expense), Other Research and Dev. decrease of 53% to $742K (expense), Depreciation/Amortization in R&D decrease of 74% to $121K (expense). more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 31st Dec '14) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2015
31st Dec 2016

Price Target: €6.00
(+25.01% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (€) (¢) (¢) (€) (¢) (¢)
Consensus Estimate
1m Change
3m Change
2 brokers Broker Consensus Trend
Broker Recommendations for MDxHealth SA
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 1 0 2

Named Brokers and Analysts
ING FM Luke Poloniecki , KBC Securities Jan Dekerpel , Petercam (Historical) Roderick Verhelst ,

Profile Summary

MDxHealth SA is a Belgium-based company that develops and commercializes epigenetic assays and service testing for cancer assessment and the personalized treatment of patients. The Company’s offerings are structured into two divisions: Clinical Molecular Diagnostics (ClinicalMDx) solutions, providing physicians with tests which aid in the identification and treatment of their cancer patients, and Pharmaco Molecular Diagnostics (PharmacoMDx) solutions, collaborating with pharmaceutical companies on the development of companion diagnostics, biomarker discovery, and clinical trial testing. Its ClinicalMDx solutions include four different product types: ConfirmMDx, InformMDx, RecurMDx and PredictMDx. MDxHealth‘s PharmacoMDx services, provided to both existing collaborators and on contracted services basis, focus on the identification and development of epigenetic biomarkers and molecular tests into companion diagnostics. The Company has one wholly owned subsidiary, MDxHealth Inc.

Directors: Jan Groen (CEO) , Francis Ota (EVF) 61, Joseph Sollee (EVP) 48, Christopher Thibodeau (EVP) 42, Wim van Criekinge (CSO) , Miriam Reyes (VOP) , Joseph Bigley (VPR) , Ming-Chou Lee (VPR) , Edward Erickson (NEC) 68, Rudi Marien (NED) 70, Rudi Pauwels (IND) 54, Ruth Devenyns (NID) 49, Mark Myslinski (NID) 58,

No. of Employees: 96 No. of Shareholders: n/a

Last Annual December 31st, 2014
Last Interim December 31st, 2014
Incorporated January 15, 2003
Public Since June 28, 2006
Shares in Issue 37,676,303
Free Float 31.5m (83.7%)
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Euronext - Brussels
Eligible for an ISA? a SIPP?

MDXH Share Price Performance MDXHQuote
0.0  0.8%
Traded 4:35pm · Minimum 15 min delayed · NMS:

Latest MDXH News Announcements (delayed)

Upcoming MDXH Events

Recent ↓
Friday 29th May, 2015 (estimate)
MDxHealth SA Annual Shareholders Meeting
Thursday 19th March, 2015
MDxHealth SA at The Wall Street Analyst Institutional Investor Conference
Thursday 13th November, 2014
MDxHealth SA at KBC Belgian Biotech & Healthcare Seminar
Thursday 2nd October, 2014
MDxHealth SA at CF&B Large & Midcap Event
Tuesday 9th September, 2014
MDxHealth SA at Rodman & Renshaw Global Investment Conference
Thursday 21st August, 2014
Q2 2014 MDxHealth SA Earnings Release
Friday 30th May, 2014
MDxHealth SA Annual Shareholders Meeting
Friday 30th May, 2014
MDxHealth SA Extraordinary Shareholders Meeting

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2015.

Should you buy MDXH

Access MDXH Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis